{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T06:16:29Z","timestamp":1788243389510,"version":"build-2803163510"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T00:00:00Z","timestamp":1783123200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T00:00:00Z","timestamp":1783123200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s40265-026-02359-1","type":"journal-article","created":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T09:15:23Z","timestamp":1783156523000},"page":"1411-1420","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Long Road to Long-Acting: What Oral PrEP and CAB-LA Teach Us About Scaling Lenacapavir"],"prefix":"10.1007","volume":"86","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8379-1001","authenticated-orcid":false,"given":"Victor Abiola","family":"Adepoju","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2939-7086","authenticated-orcid":false,"given":"Abdulrakib","family":"Abdulrahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-2421-3953","authenticated-orcid":false,"given":"Shankar","family":"Biswas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,4]]},"reference":[{"key":"2359_CR1","unstructured":"World Health Organization. HIV data and statistics 2025. https:\/\/www.who.int\/teams\/global-hiv-hepatitis-and-stis-programmes\/hiv\/strategic-information\/hiv-data-and-statistics. Accessed 2 Dec 2025."},{"key":"2359_CR2","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1007\/s40265-025-02181-1","volume":"85","author":"JM Garland","year":"2025","unstructured":"Garland JM, Mayan H, Kantor R. Treatment of advanced HIV in the modern era. Drugs. 2025;85:883\u2013909. https:\/\/doi.org\/10.1007\/s40265-025-02181-1.","journal-title":"Drugs"},{"key":"2359_CR3","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1007\/s11121-023-01554-w","volume":"24","author":"DT Dangerfield","year":"2023","unstructured":"Dangerfield DT, Davis G, Pandian V, Anderson JN. Using motivational interviewing to increase HIV PrEP initiation and adherence: a scoping review. Prev Sci. 2023;24:1365\u201375. https:\/\/doi.org\/10.1007\/s11121-023-01554-w.","journal-title":"Prev Sci"},{"key":"2359_CR4","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1097\/COH.0000000000000899","volume":"20","author":"RR Patel","year":"2025","unstructured":"Patel RR, Mayer KH. Why is roll-out of long-acting PrEP agents so slow? Curr Opin HIV AIDS. 2025;20:48\u201353. https:\/\/doi.org\/10.1097\/COH.0000000000000899.","journal-title":"Curr Opin HIV AIDS"},{"key":"2359_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.dcit.2026.100075","volume":"4","author":"VA Adepoju","year":"2026","unstructured":"Adepoju VA, Abdulrahim A, Jamil S. Breaking barriers for key populations in the lenacapavir era. Decod Infect Transm. 2026;4:100075. https:\/\/doi.org\/10.1016\/j.dcit.2026.100075.","journal-title":"Decod Infect Transm"},{"key":"2359_CR6","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1186\/s12939-025-02610-3","volume":"24","author":"VA Adepoju","year":"2025","unstructured":"Adepoju VA, Abdulrahim A. Dollars and dilemmas: lenacapavir\u2019s pricing, patents, and the path to affordability. Int J Equity Health. 2025;24:270. https:\/\/doi.org\/10.1186\/s12939-025-02610-3.","journal-title":"Int J Equity Health"},{"key":"2359_CR7","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1111\/hiv.13748","volume":"26","author":"K Alford","year":"2025","unstructured":"Alford K, Sidat S, Bristowe K, Cicconi P, Vera JH, Cresswell F. Lenacapavir: patient and healthcare provider perceptions and the potential role for a twice-yearly injectable HIV treatment. HIV Med. 2025;26:441\u201350. https:\/\/doi.org\/10.1111\/hiv.13748.","journal-title":"HIV Med"},{"key":"2359_CR8","unstructured":"Gilead. Gilead presents full PURPOSE 2 data results for twice yearly lenacapavir for HIV prevention at HIV Glasgow 2024. https:\/\/www.gilead.com\/news\/news-details\/2024\/gilead-presents-full-purpose-2-data-results-for-twice-yearly-lenacapavir-for-hiv-prevention-at-hiv-glasgow. Accessed 6 July 2025."},{"key":"2359_CR9","unstructured":"Gilead. Yeztugo lenacapavir is now the first and only FDA approved HIV prevention option offering 6 months of protection 2025. https:\/\/www.gilead.com\/news\/news-details\/2025\/yeztugo-lenacapavir-is-now-the-first-and-only-fda-approved-hiv-prevention-option-offering-6-months-of-protection. Accessed 22 June 2025."},{"key":"2359_CR10","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1056\/NEJMoa2411858","volume":"392","author":"CF Kelley","year":"2025","unstructured":"Kelley CF, Acevedo-Qui\u00f1ones M, Agwu AL, Avihingsanon A, Benson P, Blumenthal J, et al. Twice-yearly lenacapavir for HIV prevention in men and gender-diverse persons. N Engl J Med. 2025;392:1261\u201376. https:\/\/doi.org\/10.1056\/NEJMoa2411858.","journal-title":"N Engl J Med"},{"key":"2359_CR11","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1056\/NEJMoa2101016","volume":"385","author":"RJ Landovitz","year":"2021","unstructured":"Landovitz RJ, Donnell D, Clement ME, Hanscom B, Cottle L, Coelho L, et al. Cabotegravir for HIV prevention in cisgender men and transgender women. N Engl J Med. 2021;385:595\u2013608. https:\/\/doi.org\/10.1056\/NEJMoa2101016.","journal-title":"N Engl J Med"},{"key":"2359_CR12","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1016\/S0140-6736(22)00538-4","volume":"399","author":"S Delany-Moretlwe","year":"2022","unstructured":"Delany-Moretlwe S, Hughes JP, Bock P, Ouma SG, Hunidzarira P, Kalonji D, et al. Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial. The Lancet. 2022;399:1779\u201389. https:\/\/doi.org\/10.1016\/S0140-6736(22)00538-4.","journal-title":"The Lancet"},{"key":"2359_CR13","unstructured":"Aziz R. AIDS 2024: Studies show strong user preference for long-acting, injectable PrEP 2024. https:\/\/www.idsociety.org\/science-speaks-blog\/2024\/aids-2024-studies-show-strong-user-preference-for-long-acting-injectable-prep\/. Accessed 6 July 2025."},{"key":"2359_CR14","unstructured":"Samuel K. Injectable PrEP use leads to zero new HIV infections among gay, trans and non-binary Brazilians. AidsmapCom 2025. https:\/\/www.aidsmap.com\/news\/mar-2025\/injectable-prep-use-leads-zero-new-hiv-infections-among-gay-trans-and-non-binary. Accessed 23 June 2025."},{"key":"2359_CR15","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1007\/s10461-022-03816-0","volume":"27","author":"K Meyers","year":"2023","unstructured":"Meyers K, Nguyen N, Zucker JE, Kutner BA, Carnevale C, Castor D, et al. The long-acting cabotegravir tail as an implementation challenge: planning for safe discontinuation. AIDS Behav. 2023;27:4\u20139. https:\/\/doi.org\/10.1007\/s10461-022-03816-0.","journal-title":"AIDS Behav"},{"key":"2359_CR16","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1016\/j.medj.2024.08.008","volume":"5","author":"S Nozza","year":"2024","unstructured":"Nozza S, Castagna A. Twice-yearly lenacapavir: a milestone for HIV prevention in young African women. Med NY N. 2024;5:1200\u20132. https:\/\/doi.org\/10.1016\/j.medj.2024.08.008.","journal-title":"Med NY N"},{"key":"2359_CR17","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1056\/NEJMoa2407001","volume":"391","author":"L-G Bekker","year":"2024","unstructured":"Bekker L-G, Das M, Abdool Karim Q, Ahmed K, Batting J, Brumskine W, et al. Twice-yearly lenacapavir or daily F\/TAF for HIV prevention in cisgender women. N Engl J Med. 2024;391:1179\u201392. https:\/\/doi.org\/10.1056\/NEJMoa2407001.","journal-title":"N Engl J Med"},{"key":"2359_CR18","unstructured":"Gilead Sciences. Yeztugo (lenacapavir) prescribing information. 2025. https:\/\/www.gilead.com\/-\/media\/files\/pdfs\/medicines\/hiv\/yeztugo\/yeztugo_pi.pdf. Accessed 16 Apr 2026."},{"key":"2359_CR19","doi-asserted-by":"publisher","first-page":"541","DOI":"10.15585\/mmwr.mm7435a1","volume":"74","author":"RR Patel","year":"2025","unstructured":"Patel RR, Hoover KW, Lale A, Cabrales J, Byrd KM, Kourtis AP. Clinical recommendation for the use of injectable lenacapavir as HIV preexposure prophylaxis\u2014United States, 2025. MMWR Morb Mortal Wkly Rep. 2025;74:541\u20139. https:\/\/doi.org\/10.15585\/mmwr.mm7435a1.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2359_CR20","unstructured":"UNAIDS. With new HIV infections rising in a growing number of countries and regions, urgent action is needed to turn the prevention crisis around 2024. https:\/\/www.unaids.org\/en\/resources\/presscentre\/pressreleaseandstatementarchive\/2024\/july\/20240724_prevention. Accessed 21 June 2025."},{"key":"2359_CR21","unstructured":"WHO. Global state of PrEP 2024. https:\/\/www.who.int\/groups\/global-prep-network\/global-state-of-prep. Accessed 6 July 2025."},{"key":"2359_CR22","unstructured":"Salud por Derecho. Lenacapavir: Gilead\u2019s voluntary licenses do not reach countries that need them 2024. https:\/\/saludporderecho.org\/en\/lenacapavir-las-licencias-voluntarias-de-gilead-no-llegan-a-paises-que-las-necesitan\/. Accessed 21 June 2025."},{"key":"2359_CR23","unstructured":"The Global Fund. Global Fund, PEPFAR announce coordinated effort to reach 2 million people with lenacapavir for PrEP to significantly reduce global HIV infections\u2014news releases\u2014The Global Fund to fight AIDS, tuberculosis and malaria 2024. https:\/\/www.theglobalfund.org\/en\/news\/2024\/2024-12-17-global-fund-pepfar-coordinated-effort-2-million-people-lenacapavir-prep\/. Accessed 21 June 2025."},{"key":"2359_CR24","unstructured":"Global Fund press release. [Press release] US and Global Fund expand commitment to long-acting HIV prevention as country rollout of lenacapavir accelerates. Eur AIDS Treat Group 2026. https:\/\/www.eatg.org\/hiv-news\/press-release-us-and-global-fund-expand-commitment-to-long-acting-hiv-prevention-as-country-rollout-of-lenacapavir-accelerates\/. Accessed 25 May 2026."},{"key":"2359_CR25","unstructured":"PrEPWatch. From clinical trial efficacy to public health impact: a plan for accelerating access to injectable lenacapavir for PrEP 2024. https:\/\/www.prepwatch.org\/resources\/from-clinical-trial-efficacy-to-public-health-impact-a-plan-for-accelerating-access-to-injectable-lenacapavir-for-prep\/. Accessed 21 June 2025."},{"key":"2359_CR26","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1007\/s11121-019-01013-5","volume":"20","author":"S Kalichman","year":"2019","unstructured":"Kalichman S, Shkembi B, Hernandez D, Katner H, Thorson KR. Income inequality, HIV stigma, and preventing HIV disease progression in rural communities. Prev Sci. 2019;20:1066\u201373. https:\/\/doi.org\/10.1007\/s11121-019-01013-5.","journal-title":"Prev Sci"},{"key":"2359_CR27","unstructured":"Neergaard L. The world\u2019s only twice-a-year shot to prevent HIV could stop transmission\u2014if people can get it - WHEC.com 2025. https:\/\/www.whec.com\/ap-top-news\/the-worlds-only-twice-a-year-shot-to-prevent-hiv-could-stop-transmission-if-people-can-get-it\/. Accessed 6 July 2025."},{"key":"2359_CR28","unstructured":"World Health Organization. Guidelines on lenacapavir for HIV prevention and testing strategies for long-acting injectable pre-exposure prophylaxis 2025. https:\/\/www.who.int\/publications\/i\/item\/9789240111608. Accessed 27 July 2025."},{"key":"2359_CR29","unstructured":"AIDS Vaccine Advocacy Coalition. Injectable lenacapavir for PrEP. PrEPWatch 2026. https:\/\/www.prepwatch.org\/products\/lenacapavir-for-prep\/. Accessed 11 June 2026."},{"key":"2359_CR30","unstructured":"Ofili F. WHO backs rollout of new HIV prevention drug in 9 countries. NEWSVERGE 2026. https:\/\/newsverge.com\/2026\/03\/06\/who-backs-rollout-of-new-hiv-prevention-drug-in-9-countries\/. Accessed 11 June 2026."},{"key":"2359_CR31","unstructured":"IOL Reporter. Lenacapavir rollout in South Africa: a groundbreaking step in HIV prevention. Afr News Agency 2026. https:\/\/africannewsagency.com\/lenacapavir-rollout-in-south-africa-a-groundbreaking-step-in-hiv-prevention\/. Accessed 11 June 2026."},{"key":"2359_CR32","first-page":"34","volume":"2026","author":"S Buchbinder","year":"2026","unstructured":"Buchbinder S, Albert YCROI. Global epidemiology and prevention of HIV and other sexually transmitted diseases. IAS-USA. 2026;2026:34.","journal-title":"IAS-USA"},{"key":"2359_CR33","unstructured":"WHO. Global Price Reporting Mechanism. 2017. https:\/\/apps.who.int\/hiv\/amds\/price\/hdd\/ Accessed 11 June 2026."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-026-02359-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-026-02359-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-026-02359-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T06:02:36Z","timestamp":1788242556000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-026-02359-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,4]]},"references-count":33,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["2359"],"URL":"https:\/\/doi.org\/10.1007\/s40265-026-02359-1","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,4]]},"assertion":[{"value":"9 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":5,"name":"Ethics","label":"Availability of data and material","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":6,"name":"Ethics","label":"Code availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"VAA conceived the idea. VAA, AA, and SB participated in manuscript writing, review, and editing, and approved the final manuscript.","order":7,"name":"Ethics","label":"Author contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}